Phase 2 Trial Will Assess Autologous Mesenchymal Stem Cell Therapy to Treat Progressive Forms of MS
The National Multiple Sclerosis Society is sponsoring a Phase 2 clinical trial to test the effectiveness of stem cell therapy on people with progressive forms of Multiple Sclerosis. Medical practitioners will take mesenchymal stem cells from a patient’s bone marrow. Next they reinject these stem cells into the patient near damaged tissue, which charges growth factors to begin the healing process.
Indeed, the study will focus on 50 patients with progressive forms on MS. Patients receive 6 injections at 2 month intervals in one year. The clinical team will test bladder function as well as any adverse side effects and do other tests to check the outcome for these patients.
Moreover, the study has started to recruit patients for this study. There are many ongoing clinical trials testing the safety and efficacy of mesenchymal stem cells on patients for various conditions. This study is a follow up from a Phase 1 study conducted in New York at Tisch MS Research.
Finally, the National Multiple Sclerosis Society donated $1 million to sponsor this study. The study is identified as NCT 03355365 and can be found at the website: www.clinicaltrials.gov. Do a search here on our website Stem Cell therapy for Multiple Sclerosis and you will find data from other clinical trials showing the results for patients.